Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Zentek Ltd. Discusses C$33 Million Financing and 2022 Goals with The Stock Day Podcast

By: Newsfile

Phoenix, Arizona--(Newsfile Corp. - January 6, 2022) - The Stock Day Podcast welcomed Zentek Ltd. (OTC Pink: ZENYF) ("the Company"), an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. CEO of the Company, Dr. Francis Dube, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's background and current projects. "We're really a healthcare, health technology company, and we've been focused on that for the last eighteen months with the COVID pandemic," said Dr. Dube. "We're basically a research and development company," he added. "We develop and commercialize IP."

"Last year, we started working on a new technology that would help make masks better," continued Dr. Dube. "When we talked last October, we had just filed a provisional patent in the US for the new technology that enabled masks to have a 99.99% bacterial and viral filtration efficiency," he explained. "Within a year we went from filing a patent to having regulatory approvals here in Canada and we have filed a 510K pre-submission in the US, and we are now also moving into Europe with our regulatory applications."

"Could you bring us up-to-date on the status of financing?" asked Jolly. "We are actually at the tail end of a $33 million Canadian raise," shared Dr. Dube. "We now have a full treasury to be able to expedite our business plan," he added. "We're going to have the capacity to produce a lot of masks, we're talking hundreds of millions of masks per month."

"We're also working on a really novel detection technology, which could help diagnose COVID within ten minutes, but at a PCR level sensitivity," said Dr. Dube.

"Are you expecting to uplist on the Nasdaq?" asked Jolly. "We officially applied to the Nasdaq on October 13th," shared Dr. Dube. "We do expect our shares to be uplisted from the Pink Sheets to the Nasdaq hopefully later this month."

The conversation then turned to the Company's 2022 goals. "We've been focused on getting our masks to market and that is still our number one project right now," said Dr. Dube. "We want to start generating revenue as a healthcare IP development company and we expect those revenues to have significant margins," he said, noting the market cap potential of those margins.

"Secondary to that is really developing our rapid detection technology," continued Dr. Dube. "We have a global exclusive license to use this technology from McMaster University," he said. "We're going to be pushing really hard to bring that to market as soon as possible."

To close the interview, Dr. Dube elaborated on the Company's significant 2021 achievements, as well as their 2022 goals, and encouraged listeners to stay up-to-date on the Company's current and upcoming projects.

To hear Francis Dube's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8008341-zentek-ltd-discusses-c-33-million-financing-and-2022-goals-with-the-stock-day-podcast.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

To find out more about Zentek Ltd., please visit our website at www.zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR profile at www.sedar.ca.

For further information:

Matt Blazei
CORE IR
(212) 655-0924
mattb@coreir.com

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109254

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.